Skip to main content

Peer Review reports

From: Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Original Submission
6 Dec 2019 Submitted Original manuscript
18 Dec 2019 Author responded Author comments - James F. Donohue
24 Feb 2020 Reviewed Reviewer Report - Sergey Avdeev
29 Feb 2020 Reviewed Reviewer Report - Sabina Antonela Antoniu
2 Mar 2020 Reviewed Reviewer Report - Maria Gabriella Matera
23 Mar 2020 Author responded Author comments - James F. Donohue
Resubmission - Version 2
18 Dec 2019 Submitted Manuscript version 2
6 Apr 2020 Author responded Author comments - James F. Donohue
Resubmission - Version 3
6 Apr 2020 Submitted Manuscript version 3
15 Apr 2020 Author responded Author comments - James F. Donohue
Resubmission - Version 4
15 Apr 2020 Submitted Manuscript version 4
Publishing
20 Apr 2020 Editorially accepted
11 May 2020 Article published 10.1186/s12890-020-1156-4

You can find further information about peer review here.

Back to article page